Recent Quotes View Full List My Watchlist Create Watchlist Indicators DJI Nasdaq Composite SPX Gold Crude Oil EL&P Market Index Markets Stocks ETFs Tools Overview News Currencies International Treasuries Dianthus Therapeutics, Inc. - Common Stock (NQ: DNTH ) 25.00 -0.63 (-2.46%) Streaming Delayed Price Updated: 9:53 AM EDT, May 20, 2024 Add to My Watchlist Quote Overview Detailed Quote Charting Historical Prices News All News News Headlines Press Releases Research Quarterly Reports Insider Filings Other Filings Price and Volume Detailed Quote Volume 1,688 Open 25.36 Bid (Size) 24.93 (4) Ask (Size) 25.45 (3) Prev. Close 25.63 Today's Range 25.00 - 25.42 52wk Range 6.580 - 33.77 Shares Outstanding N/A Dividend Yield N/A Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year Top News More News What 5 Analyst Ratings Have To Say About Dianthus Therapeutics May 10, 2024 Via Benzinga DNTH Stock Earnings: Dianthus Therapeutics Misses EPS, Beats Revenue for Q1 2024 May 09, 2024 DNTH stock results show that Dianthus Therapeutics missed analyst estimates for earnings per share but beat on revenue for the first quarter of 2024. Via InvestorPlace Performance YTD +118.34% +118.34% 1 Month +7.53% +7.53% 3 Month +4.73% +4.73% 6 Month +115.15% +115.15% 1 Year +127.27% +127.27% More News Read More Dianthus Therapeutics Highlights Recent Business Achievements and Reports Q1 Financial Results May 09, 2024 From Dianthus Therapeutics, Inc. Via GlobeNewswire Dianthus Therapeutics to Participate in the Bank of America Securities 2024 Health Care Conference May 08, 2024 From Dianthus Therapeutics, Inc. Via GlobeNewswire What 5 Analyst Ratings Have To Say About Dianthus Therapeutics April 18, 2024 Via Benzinga Decoding 4 Analyst Evaluations For Dianthus Therapeutics February 15, 2024 Via Benzinga Why Dianthus Therapeutics (DNTH) Stock Is Exploding Higher January 22, 2024 Via Benzinga Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) May 03, 2024 From Dianthus Therapeutics, Inc. Via GlobeNewswire Dianthus Therapeutics Announces Oral Presentation for DNTH103 at the 2024 American Academy of Neurology (AAN) Annual Meeting April 11, 2024 From Dianthus Therapeutics, Inc. Via GlobeNewswire Dianthus Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) April 05, 2024 From Dianthus Therapeutics, Inc. Via GlobeNewswire Why Cutera Shares Are Trading Lower By Over 26%? Here Are Other Stocks Moving In Friday's Mid-Day Session March 22, 2024 Via Benzinga Worthington Steel Posts Upbeat Results, Joins Summit Midstream Partners, FedEx And Other Big Stocks Moving Higher On Friday March 22, 2024 Via Benzinga Topics Stocks Exposures US Equities DNTH Stock Earnings: Dianthus Therapeutics Beats EPS, Beats Revenue for Q4 2023 March 21, 2024 Via InvestorPlace Dianthus Therapeutics Announces Inducement Grant Under Nasdaq Listing Rule 5635(c)(4) March 07, 2024 From Dianthus Therapeutics, Inc. Via GlobeNewswire Dianthus Therapeutics Announces Initiation of Phase 2 MaGic Trial of DNTH103 In Generalized Myasthenia Gravis (gMG) February 26, 2024 From Dianthus Therapeutics, Inc. Via GlobeNewswire DNTH Stock Earnings: Dianthus Therapeutics Reported Results for Q3 2023 December 14, 2023 Via InvestorPlace Antibody Player Dianthus Therapeutics Has Potential Amid Active M&A Landscape in Complement-Focused Firms: Analyst November 22, 2023 Via Benzinga Dianthus' Monoclonal Antibody On Promising Pathway To Gaining The Upper Hand - Analyst September 28, 2023 Via Benzinga Benzinga's Top Ratings Upgrades, Downgrades For September 28, 2023 September 28, 2023 Via Benzinga Data & News supplied by www.cloudquote.io Stock quotes supplied by Barchart Quotes delayed at least 20 minutes. By accessing this page, you agree to the following Privacy Policy and Terms and Conditions.
